Glaukos/GKOS

$97.82

2.82%
-
1D1W1MYTD1YMAX

About Glaukos

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Ticker

GKOS

Sector

Healthcare

Trading on

NYSE

Industry

Medical Equipment & Supplies

CEO

Thomas Burns

Employees

907

Headquarters

Aliso viejo, United States

Glaukos Metrics

BasicAdvanced
$4.84B
Market cap
-
P/E ratio
-$2.78
EPS
1.08
Beta
-
Dividend rate
$4.84B
1.07963
$102.33
$45.38
679.65K
5.343
4.776
76.513
76.513
-27.68%
-13.86%
-27.16%
-14.99%
15.386
10.307
42.975
11.26%
-32.97%
11.84%

What the Analysts think about Glaukos

Analyst Ratings

Majority rating from 14 analysts.
Buy

Price Targets

Average projection from 11 analysts.
8.92% upside
High $120.00
Low $84.00
$97.82
Current price
$106.55
Average price target

Glaukos Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-44.59% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$82.3M
5.51%
Net income
$-36.7M
20.72%
Profit margin
-44.59%
14.42%

Glaukos Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 14.58%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.59
-$0.55
-$0.50
-$0.63
-
Expected
-$0.58
-$0.55
-$0.55
-$0.55
-$0.58
Surprise
2.58%
-0.81%
-8.88%
14.58%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Glaukos stock?

Glaukos (GKOS) has a market cap of $4.84B as of April 19, 2024.

What is the P/E ratio for Glaukos stock?

The price to earnings (P/E) ratio for Glaukos (GKOS) stock is 0 as of April 19, 2024.

Does Glaukos stock pay dividends?

No, Glaukos (GKOS) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Glaukos dividend payment date?

Glaukos (GKOS) stock does not pay dividends to its shareholders.

What is the beta indicator for Glaukos?

Glaukos (GKOS) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Glaukos stock price target?

The target price for Glaukos (GKOS) stock is $106.55, which is 8.92% above the current price of $97.82. This is an average based on projections from 11 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Glaukos stock

Buy or sell Glaukos stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing